Aesica has established a new high-capacity manufacturing facility following a $45 million investment at its Queenborough, Kent site. The 10,000-sq.-m. expansion has been constructed for the production of a solid dose medication used in treating one of the world’s most common lifestyle diseases: Type 2 diabetes in adults.
The facility contains a large amount of highly technical and specialist equipment including spray granulators, coaters, tablet presses, a delumper, blender and a sieve system. Commercial production at the facility will commence in November. The product manufactured at the new facility has global sales and is set for worldwide export.
Aesica will have a dedicated workforce of 55 technicians at the Queenborough, who will be recruited locally and trained on site. The design of the facility will allow the current capacity to be more than doubled in the future, which could lead to another 50 people to be recruited.
Dr. Robert Hardy, chief executive officer of Aesica Pharmaceuticals, commented, “The new investment and opening of this facility marks another key milestone for our company and a further step towards achieving our vision to be the world’s number one supplier of APIs and formulated products to the pharmaceutical industry."